The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.
Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]epitype.de
Internet: www.epitype.de
Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn moreI acceptWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Datenschutz
Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
Press ReleasesCancer is and remains one of the greatest health, medical and socio-political challenges of our time. This is also made clear by the World Health Organization’s (WHO) forecast, which predicts […]
Jena Biotechnology Company Files for Insolvency
Press ReleasesJena, Thuringia, March 31, 2025. Jena-based Oncgnostics GmbH has filed for insolvency. The Gera District Court has ordered and appointed lawyer Kai Dellit from the law firm hww hermann wienberg […]
Bachelor thesis in biotechnology companies: From research to diagnostics
BlogWhat can emerge from basic research? This question followed Lena Bernstein during her studies in Biochemistry and Molecular Biology at the University of Jena. To find answers, she chose to […]
Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%
Press ReleasesPorto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain […]
Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics
Press ReleasesJena / Düsseldorf, November 7, 2024 – Molecular biological diagnostics offer a non-invasive alternative for cancer detection. oncgnostics GmbH will demonstrate this in Düsseldorf at MEDICA, one of the world’s […]
Oncgnostics expands international distribution
Press ReleasesJena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement […]
Psychological stress in cervical cancer tabood
Press ReleasesMedia study: A recent media study by Oncgnostics GmbH shows that, although the general media report on the topic of cervical cancer, they do not address the associated psychological stress […]
Molecular biological cancer diagnostics close gaps in cancer screening
Press ReleasesTwo tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]
Hong Kong firm invests in Jena-based Oncgnostics GmbH
Press ReleasesJena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]
Harald zur Hausen – in memory of a pioneer of cancer prevention
BlogProf. Dr Harald zur Hausen died on 28 May 2023. With his research, he laid the foundation for a new way of cancer prevention. We at oncgnostics commemorate the internationally […]